Author

Ray J. Hohl

Observed names: R HOHL, R Hohl, R J Hohl, R. Hohl, R. J. Hohl, R.J. Hohl, RJ Hohl, Ray Hohl, RaymondJ. Hohl

Institution: Penn State Cancer Institute

Observed institutions: University of Iowa, Pennsylvania State University, Memorial Sloan Kettering Cancer Center, University of California, San Francisco, University of Iowa Hospitals and Clinics, University of California San Diego, Dana-Farber Cancer Institute, Duke Medical Center, Institut Bergonié, University of Iowa Health Care, Fondazione IRCCS Istituto Nazionale dei Tumori, University of Iowa Holden Comprehensive Cancer Center, Penn State Cancer Institute

OpenAlex ID: A5113572519

O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate

2017 · Joshua D. Schoenfeld, Zita A. Sibenaller, et al. · Cancer Cell · 442

PDF

O2⋅− and H2O2-Mediated Disruption of Fe Metabolism Causes the Differential Susceptibility of NSCLC and GBM Cancer Cells to Pharmacological Ascorbate

2017 · Joshua D. Schoenfeld, Zita A. Sibenaller, et al. · Cancer Cell · 131

PDF

Changes in Erythropoietin Pharmacokinetics following Busulfan-Induced Bone Marrow Ablation in Sheep: Evidence for Bone Marrow as a Major Erythropoietin Elimination Pathway

2001 · S. Chapel, P. Veng-Pedersen, et al. · Journal of Pharmacology and Experimental Therapeutics · 69

Phase II study of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma: CALGB 90207

2008 · J.E. Rosenberg, S. Halabi, et al. · Annals of Oncology · 52

PDF

Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas

2011 · Thomas E. Witzig, Hui Tang, et al. · Blood · 46

A phase I trial of perillyl alcohol administered four times daily for 14�days out of 28�days

2004 · HowardH. Bailey, George Wilding, et al. · Cancer Chemotherapy and Pharmacology · 32

Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy‐induced anemia and bone marrow ablation

2004 · P. Veng‐Pedersen, S. Chapel, et al. · Biopharmaceutics & Drug Disposition · 28

Change in Erythropoietin Pharmacokinetics Following Hematopoietic Transplantation

2007 · J A Widness, R L Schmidt, et al. · Clinical Pharmacology & Therapeutics · 27

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

2006 · David S. Siegel, A. Krishnan, et al. · Blood · 20

Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers

2003 · S. R. Vanapalli, Y. Chen, et al. · Clinical Pharmacology & Therapeutics · 19

A Differential Pharmacokinetic Analysis of the Erythropoietin Receptor Population in Newborn and Adult Sheep

2003 · P. Veng-Pedersen, S. Chapel, et al. · Journal of Pharmacology and Experimental Therapeutics · 10

A phase II clinical trial of neoadjuvant trabectedin in patients with nonmetastatic advanced myxoid/round cell liposarcoma (MRCL)

2009 · A. Gronchi, A. Le Cesne, et al. · Journal of Clinical Oncology · 8

Cancer Therapy: Shooting for the Moon

2017 · JSH Lee, GM Blumenthal, et al. · Clinical Pharmacology & Therapeutics · 5

PDF

CALGB 90207: Phase II trial of bortezomib in patients with previously treated advanced urothelial tract transitional cell carcinoma (TCC)

2006 · J. E. Rosenberg, S. Halabi, et al. · Journal of Clinical Oncology · 3

A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation

2002 · C-K Lee, M deMagalhaes-Silverman, et al. · Bone Marrow Transplantation · 2

Phase 1 study of irinotecan (CPT-11) in patients with abnormal liver or renal function or with prior pelvic radiation therapy

2001 · A. Venook, C. Klein, et al. · 2

Risk Factors for CMV Infection, Including HLA Disparity and Ptcy Transplant in the Era of Letermovir Prophylaxis

2023 · Nyein Yu, Jeffery Sivik, et al. · Blood

PDF

Change in erythropoietin pharmacokinetics in patients receiving hematopoietic stem cell transplantation

2005 · R HOHL, J WIDNESS, et al. · Clinical Pharmacology & Therapeutics

71 T-cell depleted allogeneic bone marrow transplantation followed by T cell add-back in patients with multiple myeloma

2003 · M. Magalhaes-Silverman, C. Lee, et al. · Transplantation and Cellular Therapy

PDF

PCD6: COMPARISON OF THE McMASTER'S HEALTH UTILITIES INDEX-MARK III AND THE EUROQOL-5D IN A SURGICAL BREAST CANCER POPULATION

1999 · MA Namjoshi, TN Taylor, et al. · Value in Health

PDF

Pca10: the Relationship Between Profile-based Quality of Life Scores and Euroqol-5d Scores in Breast Cancer Surgery Patients

1999 · M Namjoshi, T Taylor, et al. · Value in Health

PDF

Abstracts

1995 · Andrew Yen, Megan Williams, et al. · Advances in experimental medicine and biology

Works count: 22

Citation count: 896

H-index: 10

I10-index: 11